See Bull Run's live company pages for Mankind Pharma and Alkem Laboratories. For another domestic-franchise comparison, see Bull Run's Cipla vs Mankind Pharma and Sun Pharma vs Mankind Pharma.

Q1 FY27 financial scorecard

Mankind is the more India-concentrated company

This creates two very different geographic risk profiles.

Mankind's earnings are overwhelmingly linked to:

• Indian prescription growth;
• domestic price regulation;
• doctor reach;
• Indian healthcare demand;
• domestic specialty execution.

Alkem has a materially larger international layer relative to company size.

Mankind's India franchise is larger in absolute terms

₹3,426 crore versus ₹2,498 crore is a difference of approximately ₹928 crore in one quarter.

Mankind has built this scale through:

• 18,500-plus field-force professionals;
• 17,600-plus stockists;
• reach to more than 500,000 doctors;
• leadership by prescription count;
• strong presence beyond only large metropolitan markets.

This breadth is one of the most difficult pharmaceutical assets to replicate.

Alkem has a similarly powerful prescription heritage

Alkem's FY26 profile ranked it approximately:

• number three in prescriptions under company-cited market data;
• number six by value in the Indian pharmaceutical market;
• a leading player in trade generics.

The company operates with more than 14,500 field-force personnel.

Its domestic strength is concentrated around several very large brand families.

Alkem built its franchise through mega brands

Alkem has historically been associated with franchises such as:

• Clavam;
• Taxim;
• PAN;
• A to Z;
• multiple gastroenterology and anti-infective brands.

Large brand families create durable physician familiarity and pharmacy availability.

They also reduce the risk that the domestic business depends on hundreds of tiny brands with little individual loyalty.

Mankind built scale differently

Mankind's historical model emphasised affordability and broad physician penetration.

Rather than relying only on a handful of mega brands, it created huge prescription and unit volumes.

This strategy helped the company penetrate Tier 2, Tier 3 and rural markets more deeply.

The next phase is improving the economic value of that distribution.

That next phase is chronic medicine

Both therefore outgrew many parts of the domestic pharmaceutical market.

This is strategically important because both companies historically had large acute businesses.

Mankind's chronic share reached around 40%

Excluding BSV, management said chronic therapies represented approximately 40% of the relevant portfolio.

That was up around 80 basis points year on year.

The medium-term objective is around 50%.

If achieved, Mankind's revenue mix would become materially more recurring.

Mankind's cardiac portfolio grew 19.4%

Cardiac growth materially outperformed the broader market.

The Telmikind family grew approximately 21%.

Lipirose and Statpure also delivered strong growth.

This shows Mankind is not merely entering chronic therapies—it is creating large scalable brands.

Anti-diabetes is another important chronic engine

Mankind's anti-diabetes portfolio excluding selected new-product effects grew around 12.7%.

The Glizid family grew around 29%.

India's diabetes burden creates a long-duration structural opportunity for companies that build strong prescriber relationships.

Alkem's chronic growth was even faster in Q1

Company-cited market data showed approximately 17.9% chronic growth versus 15.4% market growth.

That represents around 250 basis points of outperformance.

Alkem has been expanding in:

• anti-diabetes;
• dermatology;
• respiratory;
• neurology;
• urology.

This reduces its historical dependence on acute anti-infective demand.

Alkem's acute business is not being sacrificed

Acute growth was approximately 12.3% versus around 10.1% for the market under company-cited data.

That is an important result.

Alkem is not merely moving money and field force away from its legacy businesses.

It is trying to grow chronic while continuing to outperform in acute.

This creates a balanced domestic model

An ideal pharmaceutical portfolio combines:

• large acute brands for scale;
• chronic therapies for repeat prescriptions;
• specialty products for higher barriers;
• international revenue for geographic diversification.

Alkem is progressively moving in that direction.

Mankind's acute portfolio is recovering

Mankind's acute growth improved from approximately 6.1% in Q1 FY26 to around 10.9% in Q1 FY27.

This matters because acute therapies still represent roughly 60% of its ex-BSV portfolio.

The company's growth therefore depends on more than chronic alone.

Gastroenterology was particularly strong

Mankind's gastro portfolio grew approximately 13.6%.

Gynaecology also outperformed the market.

Its IVF-related portfolio delivered very strong growth.

This increasingly overlaps with BSV's fertility capabilities.

BSV changes Mankind's quality profile

This is a strategically different business from mass-market tablets.

BSV products can require:

• complex manufacturing;
• specialist physician relationships;
• biologic capabilities;
• fertility-clinic relationships;
• higher scientific barriers.

The acquisition therefore raises the potential revenue earned from each specialist relationship.

Alkem has its own biotech platform through Enzene

Enzene Biosciences develops and manufactures biosimilars.

Its platform includes oncology and other complex biologic therapies.

It also participates in CDMO services for biotechnology companies.

This gives Alkem exposure to higher-barrier biological manufacturing without requiring the entire parent company to transform overnight.

BSV and Enzene are different strategic assets

Both move the parent companies away from pure conventional branded generics.

They do so through different economics.

Alkem is also moving into metabolic therapies

Alkem launched semaglutide in India during 2026.

It introduced multiple delivery formats, including injection pens and single-shot pre-filled syringes.

The pre-filled syringes were launched with pricing starting around ₹350 for selected strengths.

This fits Alkem's historical strategy of using affordability to broaden therapy access.

Semaglutide could strengthen Alkem's chronic transition

Metabolic therapies provide exposure to:

• type 2 diabetes;
• obesity management;
• long-duration therapy;
• high-growth specialist prescribing.

The commercial opportunity is large.

Competition is also likely to be intense.

Low price alone therefore does not guarantee market leadership.

Mankind currently has the better consolidated margin

Mankind generated approximately ₹1,060 crore EBITDA.

EBITDA margin was 26.3%.

Alkem generated approximately ₹766 crore EBITDA at 20.5%.

The gap is nearly 580 basis points.

Why is Mankind's margin higher?

Its economics benefit from:

• high domestic branded-pharma concentration;
• specialty contribution from BSV;
• increasing chronic mix;
• operating leverage;
• improved gross margin.

Mankind's Q1 gross margin reached approximately 72.8%.

Alkem's margin declined year on year

Alkem EBITDA increased approximately 3.7% despite revenue growing 10.9%.

EBITDA margin declined to 20.5% from approximately 21.9%.

R&D investment increased.

Operating expenses also increased.

This reduced profit conversion.

Alkem's gross margin actually improved

Gross margin increased to approximately 67.9% from 65.3%.

This shows the EBITDA pressure did not originate simply from product gross margin.

Higher operating and investment expenses absorbed the improvement.

Mankind's PAT grew while Alkem's fell

Mankind PAT increased approximately 29.1% to ₹574 crore.

Alkem PAT fell approximately 21.7% to ₹520 crore.

The absolute PAT gap was only around ₹54 crore.

This is surprisingly small given Mankind's higher EBITDA.

Alkem's PAT decline needs tax context

This is important for interpreting the quarter.

Alkem's underlying operating performance was much more stable than the headline PAT decline suggests.

EBITDA still increased.

PBT before exceptional items increased slightly.

R&D intensity is lower at Alkem than at many global peers

Alkem invested approximately ₹150 crore in Q1 R&D.

That was around 4% of revenue.

The amount increased materially year on year.

The company is investing across:

• generic filings;
• biosimilars;
• new formulations;
• international opportunities;
• MedTech and biotech capabilities.

Mankind's R&D strategy is also changing

Mankind historically relied heavily on branded generics and commercial execution.

It is increasingly building science-led capabilities through:

• BSV;
• specialty medicines;
• in-licensing;
• AI-assisted drug discovery collaborations;
• internal R&D.

This should gradually make Mankind less dependent on purely commercial distribution advantages.

International diversification strongly favours Alkem

Alkem generated approximately ₹1,222 crore of international sales.

Mankind generated approximately ₹605 crore of international revenue.

Alkem therefore generated roughly twice Mankind's international revenue despite being the smaller consolidated company.

Alkem's international business grew 16%

The US generated approximately ₹744 crore and grew 6.5%.

Non-US international sales generated approximately ₹479 crore and grew 34.5%.

This provides significant geographic diversification.

Mankind's international business grew much faster

International revenue increased approximately 29%.

But it still represents only around 15% of group revenue.

This means the smaller base can support strong future growth if Mankind expands successfully.

Alkem's US business also brings regulatory risk

OAI is a meaningful regulatory issue.

It can potentially affect:

• new product approvals linked to the facility;
• inspection frequency;
• remediation expenses;
• management attention;
• customer confidence.

It should not be ignored merely because the stock is cheaper.

Other Alkem facilities have better status

The Baddi formulations facility had received an Establishment Inspection Report from its earlier inspection.

Its Taloja bioequivalence centre had no observation in the April 2026 inspection.

Several API facilities also had completed prior inspections satisfactorily.

Regulatory risk therefore should be evaluated facility by facility.

Mankind's major risk is more financial than regulatory today

The BSV acquisition required significant capital.

Mankind continues reducing that debt.

Net debt fell to approximately ₹3,377 crore.

Net debt to adjusted EBITDA improved to around 0.9x.

This is a manageable level, but the acquisition still needs to produce attractive returns on invested capital.

Alkem has the opposite balance-sheet setup

This balance-sheet difference directly affects valuation risk

Alkem can fund R&D, Enzene, semaglutide expansion and MedTech investment largely from internal liquidity.

Mankind must balance growth investment with deleveraging.

That does not make Mankind financially weak.

It simply means capital allocation carries more consequences.

Current ROCE strongly favours Alkem

Alkem currently earns significantly more return on capital.

Its free-cash-flow history is also slightly stronger under Bull Run's standardized data.

Mankind needs the BSV acquisition and chronic transition to lift ROCE over time.

The market values Mankind 55% higher

Mankind's market capitalisation is approximately ₹1.05 lakh crore.

Alkem's is approximately ₹67,700 crore.

Mankind is therefore worth roughly 55% more in the market.

Yet Q1 revenue was only around 8% higher.

PAT was only around 10% higher.

The valuation premium therefore reflects expectations, not current scale alone.

Valuation is the strongest argument for Alkem

Alkem is cheaper on both P/E and price-to-book.

It also has higher ROCE and ROE.

On current standardized financial metrics alone, Alkem has the stronger value profile.

Why does Mankind receive such a large premium?

The market is paying for:

• prescription leadership;
• large field-force reach;
• stronger EBITDA margins;
• 15.8% chronic growth;
• BSV specialty exposure;
• 29% international growth;
• deleveraging;
• long-duration India healthcare growth.

The premium assumes those strengths eventually lift Mankind's capital returns.

Why is Alkem cheaper despite higher ROCE?

Several factors can explain the discount:

• greater historical acute exposure;
• lower EBITDA margin;
• current PAT decline;
• Daman regulatory uncertainty;
• more conventional generic exposure internationally;
• lower perceived specialty optionality.

The cheapness is therefore not free of risk.

Alkem's chronic growth may be underestimated by the market

One of the most interesting Q1 facts is that Alkem's chronic growth reached approximately 17.9%.

That is faster than Mankind's 15.8% chronic growth in their respective disclosed datasets.

Alkem remains identified strongly with acute therapies.

If chronic growth persists, the market may gradually reassess its revenue quality.

Mankind's specialty transition remains much further advanced

BSV immediately gives Mankind a larger specialty platform.

Alkem's Enzene and newer initiatives are important but smaller relative to the parent company.

Mankind therefore has greater near-term specialty revenue impact.

What must Mankind prove?

• Chronic share should continue rising toward 50%.
• Cardiac and anti-diabetes growth must remain above market.
• BSV should sustain strong specialty growth.
• Acute recovery should remain stable.
• International revenue needs continued expansion.
• Net debt should keep falling.
• ROCE must improve enough to justify a 51x P/E.

What must Alkem prove?

• Chronic growth should remain sustainably above market.
• Legacy acute brands need continued outperformance.
• Daman OAI remediation must progress satisfactorily.
• US revenue should grow without additional regulatory disruption.
• Enzene needs increasing commercial contribution.
• Semaglutide should build a profitable franchise.
• Higher R&D spending needs commercial returns.
• Net cash must be allocated without reducing ROCE.

What could make Mankind outperform Alkem?

A successful transformation from volume leader to specialty-and-chronic leader.

If Mankind moves chronic share toward 50%, BSV compounds quickly and acquisition debt disappears, its EBITDA margin and ROCE can both improve.

That would provide stronger support for the current premium valuation.

What could make Alkem outperform Mankind?

Continued chronic outperformance combined with regulatory normalization.

Alkem does not need a dramatic rerating in its business model.

If chronic growth remains near the high teens, the Daman issue is resolved and net cash continues compounding, its 31x P/E provides a much lower hurdle than Mankind's 51x.

Which has the larger India franchise?

Mankind Pharma.

Domestic revenue was approximately ₹3,426 crore versus Alkem India sales of ₹2,498 crore.

Which has faster chronic growth?

Alkem in the companies' Q1 disclosed datasets.

Alkem reported approximately 17.9% chronic market growth versus Mankind's portfolio growth of 15.8%.

The definitions are not identical, so the comparison should be treated directionally.

Which has stronger acute growth?

Alkem.

Its acute segment grew approximately 12.3% versus Mankind around 10.9%.

Which has higher margins?

Mankind Pharma.

Its Q1 EBITDA margin was 26.3% versus Alkem at 20.5%.

Which has the stronger balance sheet?

Alkem Laboratories.

It reported roughly ₹5,764 crore net cash while Mankind carried approximately ₹3,377 crore net debt.

Which has higher ROCE?

Alkem Laboratories.

Bull Run's standardized ROCE is approximately 20.3% versus Mankind at 13.6%.

Which stock is cheaper?

Alkem by a substantial margin.

Its trailing P/E is approximately 31.4x versus Mankind around 51.3x.

Which is better: Mankind Pharma or Alkem Laboratories?

Mankind Pharma currently has the stronger domestic-scale and margin profile. It has India's larger prescription-distribution engine, higher EBITDA margins, faster PAT growth and a meaningful specialty platform through BSV.

Alkem Laboratories currently has the stronger valuation-and-capital-efficiency profile. It trades at a much lower P/E, has higher ROCE, holds substantial net cash and is growing both acute and chronic therapies faster than the relevant market benchmarks.

Alkem also has the larger international business.

Mankind has the more advanced specialty transformation.

The deciding question is whether Mankind's future quality improvement justifies paying approximately 63% more per rupee of trailing earnings.

At September 2026 valuations, Alkem offers the lower valuation hurdle and stronger current capital efficiency, but investors must monitor its Daman regulatory issue. Mankind offers greater long-duration specialty and chronic upside, but BSV integration and deleveraging need to push ROCE meaningfully higher to justify the current premium.

Frequently asked questions